UNITED STATES

SECURITIES AND EXCHANGE COMMISSION ~~WASHINGTON, D.C. 20549~~

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 2016, ~~2017~~2018

(Exact name of registrant as specified in its charter)

Wyoming		333-177122		46-0525223
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

685 Citadel Drive East - Suite ~~290~~290Colorado ~~Colorado~~ Springs, CO 80909 (Address of principal executive offices)(Zip Code) ~~Registrant’s telephone number, including area code: 719-466-6699 N/A (Former name or former address, if changed since last report)~~

Registrant’s telephone number, including area code: 719-466-6699

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ~~[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~

[ ] ~~Pre-commencement~~Soliciting ~~communications~~material pursuant to Rule ~~14d~~14a-~~2(b)~~12 under the Exchange Act (17 CFR 240.~~14d~~14a-~~2(b~~12)~~) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~

~~Item~~[ ] ~~5.02,~~Pre-commencement ~~Departure~~communications ofpursuant ~~Directors~~to orRule ~~Principal~~14d-2(b) ~~Officers;~~under ~~Election~~the ofExchange ~~Directors;~~Act ~~Appointment~~(17 ofCFR ~~Principal Officers;~~240.14d-2(b))

~~Health~~[ ] ~~Advance~~Pre-commencement ~~Inc.~~communications ~~('HADV'~~pursuant orto ~~the~~Rule ~~'the Company'~~13e-4(c), ~~announces~~under ~~that Mr. Jordan Starkman has resigned from~~ the ~~Board~~Exchange ofAct ~~Directors of HADV~~ (~~the~~17 ~~'Board'),~~CFR ~~as well as from the position of Board Executive, President, and Director with his resignation taking effect from November 1, 2017~~240. Mr. Starkman has been a Board Executive, Director, and President since the Company's inception. Health Advance Inc. would like to thank Mr. Starkman for his time and dedication and we wish him well in his future business ventures.13e-4(c))

~~The~~On ~~Company~~January ~~appoints Vice Chairman and Director~~11, ~~Gregory~~2018 ~~Shusterman~~the asCompany ~~the~~has ~~Chairman~~adopted ofa ~~the~~new Board ~~and~~Resolution ~~Executive~~as ~~Director,~~result ~~Christian~~of ~~Diesveld as~~ a ~~voting~~special ~~Director~~meeting ofwith the Board, ~~and~~of ~~Dr.~~Directors ~~Muhammad Mukhtar as the Special Advisor to the Chairman~~ and ~~shall be~~ the ~~appointed~~Shareholders ~~(Interim)~~as ~~Chief Executive Officer and a non-voting Director of the Board.~~follows:

~~Thereby,~~[i] ~~Mr.~~The Company has elected Gregory Shusterman, ~~Mr.~~as ~~Diesveld,~~the ~~and~~President ~~Dr. Mukhtar’s appointment are~~ [Officer], effective ~~from~~ ~~November 1~~immediately, ~~2017.~~and ~~HADV~~he ~~intends~~shall toremain ~~simplify~~the ~~its~~Executive ~~overall~~Director ~~management structure~~ and isChairman inof the ~~process~~Board of ~~hiring~~Directors ~~and electing new executive management~~ for the ~~new fiscal year~~Corporation.

~~Mr.~~[ii] ~~Shusterman~~The isCompany ~~a Canadian citizen who~~ has ~~worked~~elected ~~previously~~Christian inDiesveld ~~various~~as ~~senior~~Secretary ~~leadership~~[Officer] ~~positions~~and ~~for~~Vice aPresident ~~number~~ of ~~companies~~Investor inRelations, ~~the~~effective ~~healthcare~~immediately, ~~industry~~ and ~~has~~he ~~work~~shall ~~experience~~remain asa ~~the~~Director ~~Vice~~of ~~Chairman and ‘Acting Chairman’ for~~ the Company ~~since being elected in April of this year~~.

Mr. ~~Diesveld~~Shusterman iswas aappointed ~~Canadian~~as ~~citizen~~Director and UKVice ~~resident~~Chairman ~~who~~at ~~has~~Health ~~worked~~Advance ~~previously~~ in ~~various~~2017, ~~senior~~and ~~leadership~~was ~~positions~~the ~~for~~Acting Chairman and Executive Director through January 2018. Before joining Health Advance he served as a ~~number~~consultant ofto ~~companies,~~national ~~including~~surgical clinics, ~~but~~MiVIP ~~not~~Surgery ~~limited~~Centers toand oBand Inc. Additionally, ~~Hantian~~Shusterman ~~Labs~~was ~~Limited~~co-founder and Executive Vice President at Gubagoo Inc., a ~~recent~~leading ~~acquisition~~customer communications solution serving thousands of ~~the~~clients ~~Company~~including Ford, ~~where~~Fiat, ~~Mr.~~Chrysler, ~~Diesveld~~BMW, ~~was~~VW, ~~recently~~Kia ~~named~~and UKLand ~~CEO~~Rover. ofHis ~~the~~entrepreneurial ~~Year~~experience –has ~~Small~~helped ~~Enterprise~~bring instart ~~the~~up ~~Health~~companies through growth and ~~Wellness~~expansion ~~sector~~phases, to maturity and exit.

DrMr. ~~Mukhtar~~Diesveld ~~has~~is ~~served as~~ a ~~professor~~Canadian atcitizen ~~the~~and ~~American~~UK ~~University~~resident ofwho ~~Ras~~has ~~Al Khaimah (AURAK), United Arab Emirates. Before his arrival at AURAK, he~~ served ~~as Vice Chancellor/Professor of three Universities~~ in ~~Pakistan~~various ~~concomitantly~~senior –leadership aroles ~~unique honor~~ for ~~any~~a ~~academic~~number ~~leader.~~of ~~Through~~companies, ~~his~~including ~~wise~~Tapout ~~academic~~Fitness, ~~leadership~~Ltd. and ~~innovative~~Hantian ~~governance~~Labs Limited, ~~he converted~~ a ~~regional~~recent ~~higher~~acquisition ~~education institution in Pakistan to one~~ of the ~~top-ranked~~Company, inwhere ~~the country~~Mr. ~~Mukhtar~~Diesveld ~~received~~was ~~his~~named ~~Master~~UK ~~and~~CEO ~~MPhil~~of in the ~~field~~Year of– Small ~~Biochemistry~~Enterprise ~~from~~Health ~~Pakistan~~ and ~~his Ph~~Wellness.D. Additionally, inDiesveld ~~biosciences~~brings ~~from~~over ~~the~~twenty ~~Drexel~~years ~~University~~experience ofin ~~Philadelphia,~~capital ~~USA~~markets, ~~and~~specializing ~~also~~in ~~completed~~private aequity ~~Graduate~~and ~~Certificate~~venture incapital ~~Research~~with ~~Management~~FCA ~~from~~licensed ~~Thomas~~firms. Deisveld ~~Jefferson~~attended York University inwhere ~~Philadelphia,~~he ~~USA.~~majored ~~He served~~ in ~~various~~International ~~academic/administrative~~Business ~~positions~~and incontinued ~~the~~to ~~USA~~Nesbitt onBurns anafter ~~outstanding~~his ~~scientist~~internship ~~(O-1) visa~~there.

~~Mukhtar~~ This isCurrent anReport ~~avid~~on ~~researcher~~Form ~~also.~~8-K ~~His~~includes ~~laboratory~~certain ~~developed~~statements anthat inare “forward-~~vitro~~looking ~~model~~statements” within the meaning of the ~~human~~Private ~~blood-brain~~Securities ~~barrier~~Litigation toReform ~~study~~Act ~~viral~~of ~~neuropathogenesis~~1995. ~~Dr.~~Any ~~Mukhtar~~statement asin ~~Principal~~this orreport Cothat is not a statement of historical fact may be deemed to be a forward-~~Investigator~~looking ~~has~~statement. ~~received~~We ~~several~~often ~~awards~~use these types of statements when discussing our plans and strategies, our anticipation of revenues from ~~organizations~~designated ~~including~~markets ~~American~~and ~~Diabetes~~statements ~~Association~~regarding the development of our businesses, ~~American~~the ~~Society~~markets for ~~Microbiology~~our services and products, ~~Diabetes~~our ~~Trust~~anticipated ~~Foundation~~capital expenditures, USoperations, ~~National~~support ~~Institutes~~systems, ofchanges ~~Health~~in regulatory requirements and other statements contained in this report regarding matters that are not historical facts. When used in this report, ~~Pfizer~~the ~~Pharmaceuticals~~words ~~(NYSE:~~“expect,” ~~PFE)~~“anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and ~~the~~other ~~Higher~~similar ~~Education~~expressions ~~Commission~~are ofgenerally ~~Pakistan~~intended to identify forward-looking statements. ~~Human~~Because ~~blood~~these forward-~~brain~~looking ~~barrier~~statements ~~model~~involve ~~developed~~risks inand ~~his~~uncertainties, ~~laboratory~~actual isresults ~~extensively~~may ~~used~~differ tomaterially ~~understand~~from ~~ferrying~~those expressed or implied by these forward-looking statements. There can be no assurance that: (i) we have correctly measured or identified all of ~~viruses~~the ~~into~~factors affecting us or the ~~brain~~extent ~~and~~of ~~finding~~their ~~cures~~likely ~~for~~impact; ~~neurological~~(ii) ~~ailments~~the publicly available information with respect to these factors on which our analysis is based is complete or accurate; (iii) our analysis is correct; or (iv) our strategy, which is based in part on this analysis, will be successful. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. Mukhtar holds specialized Certificates in Public Health and Bioinformatics. Committed to the role of technology in biomedical research, he serves as managing editor of Frontiers in Bioscience and is on the editorial board of several research journals. He feels pride in mentoring researchers, scientists, teachers and administrators and committed professionals aspiring to excel in their practical life. He has several research publications, including peer- reviewed research, review articles, invited articles, book chapters, commissioned articles and critiques to his credit. A book describing accomplishments of Dr. Mukhtar’s educational leadership has been published in Urdu language entitled “Hayat Zauq e Safar Kay Siwa Kuch Aur Naheen” and it’s English Version “The Making of a Best National University” is in progress.

Reference is made to this disclosure set under Item 6 of this SEC Form 8-K and SEC Form 10-Q/A for the transition period from February 1, 2017 through April 30, 2017, which include Item 6 - Exhibits [99.2 and 99.3] of this Report, which disclosure is incorporated herein by reference, in addition to being pursuant to the results of Civil Case No. 17CV132-S, U.S. Court of Wyoming District on September 22, 2017.

Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1: Letter of Resignation Undersigned by Jordan Starkman

This Current Report on Form 8-K includes certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this report that is not a statement of historical fact may be deemed to be a forward-looking statement. We often use these types of statements when discussing our plans and strategies, our anticipation of revenues from designated markets and statements regarding the development of our businesses, the markets for our services and products, our anticipated capital expenditures, operations, support systems, changes in regulatory requirements and other statements contained in this report regarding matters that are not historical facts. When used in this report, the words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and other similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. There can be no assurance that: (i) we have correctly measured or identified all of the factors affecting us or the extent of their likely impact; (ii) the publicly available information with respect to these factors on which our analysis is based iscomplete or accurate; (iii) our analysis is correct; or (iv) our strategy, which is based in part on this analysis, will be successful. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Health Advance Inc.
Date: November 20, 2017	X	Gregory Shusterman
		Gregory Shusterman
		Executive Director;
		Chairman of the Board of Directors

Health Advance Inc.

Date: January 16, 2018X [s] Gregory Shusterman____

Gregory Shusterman

President; Chairman

Filing Compare · HEALTH ADVANCE INC.